Primary and Ipilimumab-induced Hypophysitis: A Single-center Case Series

References

• Faje A. Hypophysitis: evaluation and management. Clin Diabetes Endocrinol. 2016;2:15. doi:10.1186/s40842-016-0034-8.
   PubMedGoogle Scholar
• Caturegli P, Newschaffer C, Olivi A, Pomper MG, Burger PC, Rose NR. Autoimmune hypophysitis. Endocr Rev. 2005;26:599–614. doi:10.1210/er.2004-0011.
   PubMed Web of Science ®Google Scholar
• Gubbi S, Hannah-Shmouni F, Verbalis JG, Koch CA. Hypophysitis: an update on the novel forms, diagnosis and management of disorders of pituitary inflammation. Best Pract Res Clin Endocrinol Metab. 2019;33(6):101371. doi:10.1016/j.beem.2019.101371.
   PubMed Web of Science ®Google Scholar
• Caturegli P, Lupi I, Landek-Salgado M, Kimura H, Rose NR. Pituitary autoimmunity: 30 years later. Autoimmun Rev. 2008;7:631–637. doi:10.1016/j.autrev.2008.04.016.
   PubMed Web of Science ®Google Scholar
• Leporati P, Landek-Salgado MA, Lupi I, Chiovato L, Caturegli P. IgG4-related hypophysitis: a new addition to the hypophysitis spectrum. J Clin Endocrinol Metab. 2011;96:1971–1980. doi:10.1210/jc.2010-2970.
   PubMed Web of Science ®Google Scholar
• Torino F, Barnabei A, De Vecchis L, Salvatori R, Corsello SM. Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease. Oncologist. 2012;17:525–535. doi:10.1634/theoncologist.2011-0404.
   PubMed Web of Science ®Google Scholar
• Angelousi A, Alexandraki KI, Tsoli M, Kaltsas G, Kassi E. Hypophysitis (including IgG4 and immunotherapy). Neuroendocrinology. 2020;110(9–10):822–835. doi:10.1159/000506903.
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Iguchi G, Bando H, et al. Autoimmune pituitary disease: new concepts with clinical implications. Endocr Rev. 2020;41(2):261–272. doi:10.1210/endrev/bnz003.
   Web of Science ®Google Scholar
• Imber BS, Lee HS, Kunwar S, Blevins LS, Aghi MK. Hypophysitis: a single-center case series. Pituitary. 2015;18:630–641. doi:10.1007/s11102-014-0622-5.
   PubMed Web of Science ®Google Scholar
• Fukuoka H. Hypophysitis. Endocrinol Metab Clin North Am. 2015;44:143–149. doi:10.1016/j.ecl.2014.10.011.
   PubMed Web of Science ®Google Scholar
• Howlett TA, Levy MJ, Robertson IJ. How reliably can autoimmune hypophysitis be diagnosed without pituitary biopsy. Clin Endocrinol (Oxf). 2010;73:18–21. doi:10.1111/j.1365-2265.2009.03765.x.
   PubMed Web of Science ®Google Scholar
• Honegger J, Schlaffer S, Menzel C, et al. Diagnosis of primary hypophysitis in Germany. J Clin Endocrinol Metab. 2015;100:3841–3849. doi:10.1210/jc.2015-2152.
   PubMed Web of Science ®Google Scholar
• Korkmaz OP, Sahin S, Ozkaya HM, et al. Primary hypophysitis: experience of a single tertiary center. Exp Clin Endocrinol Diabetes Off J Ger Soc Endocrinol Ger Diabetes Assoc. 2019. doi:10.1055/a-0919-4388.
   Google Scholar
• Park SM, Bae JC, Joung JY, et al. Clinical characteristics, management, and outcome of 22 cases of primary hypophysitis. Endocrinol Metab. 2014;29:470–478. doi:10.3803/EnM.2014.29.4.470.
   Google Scholar
• Khare S, Jagtap VS, Budyal SR, et al. Primary (autoimmune) hypophysitis: a single centre experience. Pituitary. 2015;18:16–22. doi:10.1007/s11102-013-0550-9.
   PubMed Web of Science ®Google Scholar
• Chiloiro S, Tartaglione T, Angelini F, et al. An overview of diagnosis of primary autoimmune hypophysitis in a prospective single-center experience. Neuroendocrinology. 2017;104:280–290. doi:10.1159/000446544.
   PubMed Web of Science ®Google Scholar
• Wang S, Wang L, Yao Y, et al. Primary lymphocytic hypophysitis: clinical characteristics and treatment of 50 cases in a single centre in China over 18 years. Clin Endocrinol (Oxf). 2017;87:177–184. doi:10.1111/cen.13354.
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Takao T, Makino S. Lymphocytic adenohypophysitis and lymphocytic infundibuloneurohypophysitis. Endocr J. 1997;44:1–10. doi:10.1507/endocrj.44.1.
   PubMed Web of Science ®Google Scholar
• O’Dwyer DT, Clifton V, Hall A, Smith R, Robinson PJ, Crock PA. Pituitary autoantibodies in lymphocytic hypophysitis target both gamma- and alpha-enolase - a link with pregnancy? Arch Physiol Biochem. 2002;110:94–98. doi:10.1076/apab.110.1.94.897.
   PubMedGoogle Scholar
• Imga NN, Yildirim AE, Baser OO, Berker D. Clinical and hormonal characteristics of patients with different types of hypophysitis: a single-center experience. Arch Endocrinol Metab. 2019;63:47–52. doi:10.20945/2359-3997000000102.
   PubMed Web of Science ®Google Scholar
• Angelousi A, Cohen C, Sosa S, et al. Clinical, endocrine and imaging characteristics of patients with primary hypophysitis. Horm Metab Res Horm Stoffwechselforschung Horm Metab. 2018;50:296–302. doi:10.1055/s-0044-101036.
   PubMed Web of Science ®Google Scholar
• Oguz SH, Soylemezoglu F, Sendur SN, et al. Clinical characteristics, management, and treatment outcomes of primary hypophysitis: a monocentric cohort. Horm Metab Res Horm Stoffwechselforschung Horm Metab. 2020;52:220–227. doi:10.1055/a-1113-7777.
   PubMed Web of Science ®Google Scholar
• Faje A. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary. 2016;19:82–92. doi:10.1007/s11102-015-0671-4.
   PubMed Web of Science ®Google Scholar
• Ricciuti A, De Remigis A, Landek-Salgado MA, et al. Detection of pituitary antibodies by immunofluorescence: approach and results in patients with pituitary diseases. J Clin Endocrinol Metab. 2014;99:1758–1766. doi:10.1210/jc.2014-1049.
   PubMed Web of Science ®Google Scholar
• Takahashi Y. Mechanisms in endocrinology: autoimmune hypopituitarism: novel mechanistic insights. Eur J Endocrinol. 2020;182:R59–R66. doi:10.1530/EJE-19-1051.
   PubMed Web of Science ®Google Scholar
• Kyriacou A, Gnanalingham K, Kearney T. Lymphocytic hypophysitis: modern day management with limited role for surgery. Pituitary. 2017;20:241–250. doi:10.1007/s11102-016-0769-3.
   PubMed Web of Science ®Google Scholar
• Leung GKK, Lopes M-BS, Thorner MO, Vance ML, Laws ER. Primary hypophysitis: a single-center experience in 16 cases. J Neurosurg. 2004;101:262–271. doi:10.3171/jns.2004.101.2.0262.
   PubMed Web of Science ®Google Scholar
• Caranci F, Leone G, Ponsiglione A, et al. Imaging findings in hypophysitis: a review. Radiol Med (Torino). 2020;125:319–328. doi:10.1007/s11547-019-01120-x.
   PubMed Web of Science ®Google Scholar
• Bellastella G, Maiorino MI, Bizzarro A, et al. Revisitation of autoimmune hypophysitis: knowledge and uncertainties on pathophysiological and clinical aspects. Pituitary. 2016;19:625–642. doi:10.1007/s11102-016-0736-z.
   PubMed Web of Science ®Google Scholar
• Gutenberg A, Hans V, Puchner MJA, et al. Primary hypophysitis: clinical-pathological correlations. Eur J Endocrinol. 2006;155:101–107. doi:10.1530/eje.1.02183.
   PubMed Web of Science ®Google Scholar
• Honegger J, Buchfelder M, Schlaffer S, et al. Treatment of primary hypophysitis in Germany. J Clin Endocrinol Metab. 2015;100:3460–3469. doi:10.1210/jc.2015-2146.
   PubMed Web of Science ®Google Scholar
• Chiloiro S, Tartaglione T, Capoluongo ED, et al. Hypophysitis outcome and factors predicting responsiveness to glucocorticoid therapy: a prospective and double-arm study. J Clin Endocrinol Metab. 2018;103:3877–3889. doi:10.1210/jc.2018-01021.
   PubMed Web of Science ®Google Scholar
• Lupi I, Cosottini M, Caturegli P, et al. Diabetes insipidus is an unfavorable prognostic factor for response to glucocorticoids in patients with autoimmune hypophysitis. Eur J Endocrinol. 2017;177:127–135. doi:10.1530/EJE-17-0123.
   PubMed Web of Science ®Google Scholar
• Albarel F, Gaudy C, Castinetti F, et al. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol. 2015;172:195–204. doi:10.1530/EJE-14-0845.
   PubMed Web of Science ®Google Scholar
• Faje AT, Sullivan R, Lawrence D, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014;99:4078–4085. doi:10.1210/jc.2014-2306.
   PubMed Web of Science ®Google Scholar
• Wei KZ, Baxter M, Casasola R. Hypophysitis induced by immune checkpoint inhibitors in a Scottish melanoma population. Melanoma Manag. 2019;6:MMT13. doi:10.2217/mmt-2018-0009.
   PubMed Web of Science ®Google Scholar
• Min L, Hodi FS, Giobbie-Hurder A, et al. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res Off J Am Assoc Cancer Res. 2015;21:749–755. doi:10.1158/1078-0432.CCR-14-2353.
   PubMed Web of Science ®Google Scholar
• Faje AT, Lawrence D, Flaherty K, et al. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer. 2018;124:3706–3714. doi:10.1002/cncr.31629.
   PubMed Web of Science ®Google Scholar
• Albarel F, Castinetti F, Brue T. MANAGEMENT OF ENDOCRINE DISEASE: immune check point inhibitors-induced hypophysitis. Eur J Endocrinol. 2019;181:R107–R118. doi:10.1530/EJE-19-0169.
   PubMedGoogle Scholar
• Del Rivero J, Cordes LM, Klubo-Gwiezdzinska J, Madan RA, Nieman LK, Gulley JL. Endocrine-related adverse events related to immune checkpoint inhibitors: proposed algorithms for management. Oncologist. 2019. doi:10.1634/theoncologist.2018-0470.
   Web of Science ®Google Scholar
• Lam T, Chan MMK, Sweeting AN, et al. Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series. Intern Med J. 2015;45:1066–1073. doi:10.1111/imj.12819.
   PubMed Web of Science ®Google Scholar